Natrol bulks up
This article was originally published in The Tan Sheet
Supplement firm's sales increase 9.6% to $20.7 mil. in the second quarter (ended June 30), with earnings of $769,000 compared to a net loss of $246,000 in the prior-year period. Natrol has focused on its core Natrol brand following the divestment of multi-level and direct marketing businesses Annasa and Tamasa in January. Weight-loss product sales as well as the consolidation of its Prolab sports nutrition business into the firm's Chatsworth, Calif. corporate headquarters also contributed to profitability, President Elliot Balbert maintained...
You may also be interested in...
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”